Vaccines as an Integral Component of Cancer Immunotherapy

This Viewpoint reviews recent preclinical developments in the use of therapeutic cancer vaccines to induce immune responses to tumor-associated antigens, alone or in combination with other therapies, such as tumor checkpoint inhibitor monoclonal antibodies, to render resistant (cold) tumor cells susceptible to T-cell antitumor activity.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research